Carcinoma de células renales
Summary
Definition
History and exam
Key diagnostic factors
- presencia de factores de riesgo
- asintomático (hallazgo incidental)
- hematuria
- dolor en fosa lumbar
- masa abdominal palpable
Other diagnostic factors
- síntomas sistémicos inespecíficos
- signos de disfunción hepática
- neuromiopatía
- edema de las extremidades inferiores
- varicocele en el escroto
- manifestación dermatológica (síndromes hereditarios)
- pérdida de la visión (von Hippel-Lindau)
Risk factors
- tabaquismo
- sexo masculino
- de más de 55 años de edad
- residencia en países desarrollados
- Etnia indígena estadounidense no hispana/nativa de Alaska
- obesidad
- hipertensión
- antecedentes familiares positivos para CCR
- antecedentes de síndromes hereditarios
- antecedentes de enfermedad renal quística adquirida
- exposición al asbesto/cadmio
- antecedentes obstétricos y exposición a estrógenos
- radiación pélvica
Diagnostic tests
1st tests to order
- TC de abdomen o de pelvis
- tomografía computarizada (CT) de tórax
- resonancia magnética (IRM) de abdomen o pelvis
- ultrasonido de abdomen o pélvico
- hemograma completo (HC)
- lactato deshidrogenasa (LDH)
- calcio corregido
- pruebas de función hepática
- perfil de coagulación
- creatinina
- TFG estimada
- análisis de orina
Tests to consider
- resonancia magnética (IRM) cerebral o de columna
- gammagrafía ósea
- biopsia
- patología quirúrgica
- evaluación genética
Emerging tests
- exploración por tomografía por emisión de positrones (TEP)
Treatment algorithm
masa renal pequeña o carcinoma de células renales (CCR) en etapa 1 o 2
carcinoma de células renales (CCR) en etapa 3
carcinoma de células renales (CCR) en etapa 4 (enfermedad metastásica)
Contributors
Authors
Rodrigo R. Pessoa, MD, PhD
Urology Fellow
Department of Urology
Mayo Clinic
Rochester
MN
Disclosures
RRP declares that he has no competing interests.
Simon Kim, MD, MPH
Associate Professor of Surgery
Associate Program Director
Anschutz Medical Campus
University of Colorado
UCSOM Division of Urology
Denver
CO
Disclosures
SK declares that he has no competing interests.
Acknowledgements
Dr Rodrigo R. Pessoa and Dr Simon Kim would like to gratefully acknowledge Dr Amishi Y. Shah, Dr Sonal Gandhi, and Jennifer J. Knox, previous contributors to this topic.
Disclosures
AYS has an unpaid advisory role for Merck pharmaceuticals. SG and JJK declare that they have no competing interests.
Peer reviewers
Stephen A. Boorjian, MD
Assistant Professor
Fox Chase Cancer Center
Philadelphia
PA
Disclosures
SAB has been reimbursed by Pfizer for serving on its speakers bureau. SAB is co-author of a reference cited in this topic.
Thomas J. Guzzo, MD, MPH
Assistant Professor of Urology and Surgery
The Hospital of the University of Pennsylvania
Philadelphia
PA
Disclosures
TJG declares that he has no competing interests.
Jonathan Waxman, BSc, MBBS, MD, FRCP
Professor of Oncology
Imperial College
London
UK
Disclosures
JW declares that he has no competing interests.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
References
Key articles
American Urological Association. Renal mass and localized renal cancer: evaluation, management, and follow up. 2021 [internet publication].Full text
Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2019 May;30(5):706-20.Full text Abstract
European Association of Urology. Renal cell carcinoma. 2023 [internet publication].Full text
American College of Radiology. ACR appropriateness criteria: post-treatment follow-up and active surveillance of clinically localized renal cell carcinoma. 2021 [internet publication].Full text
Rathmell WK, Rumble RB, Van Veldhuizen PJ, et al. Management of metastatic clear cell renal cell carcinoma: ASCO guideline. J Clin Oncol. 2022 Sep 1;40(25):2957-95.Full text Abstract
Reference articles
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
Differentials
- Quiste renal benigno
- Cáncer ureteral
- Cáncer de vejiga
More DifferentialsGuidelines
- Suspected cancer: recognition and referral
- NCCN clinical practice guidelines in oncology: kidney cancer
More GuidelinesPatient information
Cáncer de riñón
More Patient information
Log in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer